Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review

被引：4

作者：

Luo, Yingzhe ^{[1
]}

Cai, Xuebin ^{[2
]}

Yang, Biao ^{[2
]}

Lu, Facheng ^{[2
]}

Yi, Cheng ^{[1
]}

Wu, Guoyu ^{[1
]}

机构：

[1] Hosp Chengdu Univ Tradit Chinese Med, Dept Oncol, Chengdu, Sichuan, Peoples R China

[2] Sichuan Univ, West China Hosp, Canc Ctr, Dept Abdominal Oncol,Div Med Oncol, Chengdu, Sichuan, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

LAG-3; immunotherapy; relatlimab; tumor; PD-1; LYMPHOCYTE-ACTIVATION GENE-3; PHASE-I; GASTRIC-CANCER; MONOCLONAL-ANTIBODY; NATURAL-KILLER; T-CELLS; PROTEIN; LIGAND; ANTI-LAG-3; GALECTIN-3;

D O I：

10.3389/fonc.2024.1402837

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lymphocyte activation gene 3 (LAG-3), also known as CD223, is an emerging immune checkpoint that follows PD-1 and CTLA-4. Several LAG-3 targeting inhibitors in clinical trials and the combination of relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) have been approved for treating - unresectable or metastatic melanoma. Despite the encouraging clinical potential of LAG-3, the physiological function and mechanism of action in tumors are still not well understood. In this review, we systematically summarized the structure of LAG-3, ligands of LAG-3, cell-specific functions and signaling of LAG-3, and the current status of LAG-3 inhibitors under development.

引用

页数：16

共 107 条

[1] MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223) [J].

Andreae, S ;

Buisson, S ;

Triebel, F .

BLOOD, 2003, 102 (06) :2130-2137

[2] Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223) [J].

Andreae, S ;

Piras, F ;

Burdin, N ;

Triebel, F .

JOURNAL OF IMMUNOLOGY, 2002, 168 (08) :3874-3880

[3] LAG3 (CD223) as a cancer immunotherapy target [J].

Andrews, Lawrence P. ;

Marciscano, Ariel E. ;

Drake, Charles G. ;

Vignali, Dario A. A. .

IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :80-96

[4]

[Anonymous], 2013, Science, V342, P1442, DOI 10.1126/science.342.6165.1442-b

[5]

Ascierto PA, 2017, ANN ONCOL, V28

[6] Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma [J].

Atkinson, Victoria ;

Khattak, Adnan ;

Haydon, Andrew ;

Eastgate, Melissa ;

Roy, Amitesh ;

Prithviraj, Prashanth ;

Mueller, Christian ;

Brignone, Chrystelle ;

Triebel, Frederic .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[7]

Avice MN, 1999, J IMMUNOL, V162, P2748

[8] Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma [J].

Bae, Jooeun ;

Accardi, Fabrizio ;

Hideshima, Teru ;

Tai, Yu-Tzu ;

Prabhala, Rao ;

Shambley, Aaron ;

Wen, Kenneth ;

Rowell, Sean ;

Richardson, Paul G. ;

Munshi, Nikhil C. ;

Anderson, Kenneth C. .

LEUKEMIA, 2022, 36 (01) :138-154

[9] CHARACTERIZATION OF THE LYMPHOCYTE-ACTIVATION GENE 3-ENCODED PROTEIN - A NEW LIGAND FOR HUMAN-LEUKOCYTE ANTIGEN CLASS-II ANTIGENS [J].

BAIXERAS, E ;

HUARD, B ;

MIOSSEC, C ;

JITSUKAWA, S ;

MARTIN, M ;

HERCEND, T ;

AUFFRAY, C ;

TRIEBEL, F ;

PIATIERTONNEAU, D .

JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (02) :327-337

[10] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

← 1 2 3 4 5 6 7 8 9 10 →